Company / SG&A Expense
TEVA PHARMACEUTICAL INDUSTRIES LTD SG&A Expense History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$1.3B
FY2025
5-year range
$1.1B / $1.3B
FY2021-FY2025
Trend
+10.9%
vs FY2024
Sector context
#20 of 213
Health Care
What the data says
Among 213 Health Care companies, TEVA PHARMACEUTICAL INDUSTRIES LTD is in the bottom 9% for sg&a expense. SG&A Expense returned to growth in FY2025 after 2 years of decline, reaching $1.3B.
Based on SEC 10-K filings.
$1.3B in FY2025 with a 5-year CAGR of +1.9%. Top quartile in the Health Care sector.
Increased from $1.2B to $1.3B over the past 2 years.
Health Care sector context is included.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- +2.9%
- 5-Year CAGR
- +1.9%
- 10-Year CAGR
- -
Sector benchmark
Bottom 9% in Health CareTop 91% of 213This company $1.3B Sector average $722.3M
▼
+78.2% above sector average
Key checks
Key Insights
- 5-year CAGR of +1.9%, indicating consistent growth.
- In FY2025, sg&a expense increased 10.9% year-over-year.
- Ranks #20 out of 213 companies in the Health Care sector.
- Peak sg&a expense was recorded in FY2017.
Company context
Key Data Points
- Altman Z-Score 0.41 (distress zone, below 1.8 threshold)
- Negative profit margin: -9.9%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $1.3B | +10.9% |
| FY2024 | $1.2B | -0.1% |
| FY2023 | $1.2B | -1.5% |
| FY2022 | $1.2B | +7.4% |
| FY2021 | $1.1B | -6.3% |
| FY2020 | $1.2B | -1.6% |
| FY2019 | $1.2B | -8.2% |
| FY2018 | $1.3B | -10.5% |
| FY2017 | $1.5B | +4.4% |
| FY2016 | $1.4B | +2.2% |
As of FY2025 · SEC 10-K · Updated Mar 28, 2026